Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...

The first investigator-initiated study of remote pulmonary artery pressure monitoring has found that it improves quality of life and reduces heart failure hospitalizations in patients with chronic ...

In patients with pulmonary arterial hypertension (PAH), the use of anticoagulants was not associated with improvement in overall survival, and these results were confirmed by an updated meta-analysis.

Health-related quality of life is an independent predictor of survival in pulmonary hypertension. Health-related quality of life (HRQOL) is poor in all forms of pulmonary hypertension (PH), according ...

Panelists discuss how pulmonary arterial hypertension diagnosis requires comprehensive evaluation including right heart catheterization to confirm hemodynamic criteria, with normal mean PA pressure ...

Please provide your email address to receive an email when new articles are posted on . Engagement in daily pulmonary artery pressure readings may benefit patients with heart failure. Patients made ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries in your lungs. It happens when these arteries become narrow or blocked, making it harder for blood to flow ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Pulmonary embolism (PE) is a potentially life-threatening situation in which a blood clot becomes lodged in an artery of the lungs, causing the blockage of blood flow. As serious as PE is, its impact ...